He Zhou Shi

Researchers are evaluating the protective effects, safety, and immune response of an 11-valent recombinant human papillomavirus HPV vaccine in Chinese women aged 18 to 45 years. This Phase III clinical trial involves 13,500 women divided into three age groups to assess the vaccines ability to prevent HPV infections and related cervical lesions. Participants are randomized into experimental and placebo groups to compare outcomes. The trial administers three doses of either the HPV vaccine or a placebo via intramuscular injections into the upper arm deltoid muscle, scheduled at 0, 2, and 6 months. The study uses a double-blind design to ensure unbiased results. The vaccine targets multiple HPV types associated with cervical cancer and related conditions. Participants will undergo follow-up visits including gynecological examinations, pregnancy testing, and monitoring for adverse events. Researchers will measure the incidence of cervical intraepithelial neoplasia CIN and HPV-related lesions, as well as antibody responses at multiple time points after vaccination. The trial includes long-term monitoring up to six years to evaluate vaccine safety and effectiveness.

Researchers are evaluating a 20-valent pneumococcal conjugate vaccine 20vPnC in healthy infants to see if it is safe and helps the body make antibodies against 20 types of pneumococcal bacteria. This study compares the 20vPnC vaccine to an approved 13-valent pneumococcal conjugate vaccine 13vPnC in infants aged 42 to 98 days at the time of consent. The goal is to assess safety and immune response in this population. Infants will receive either the 20vPnC or 13vPnC vaccine in four doses three doses given approximately at 2, 4, and 6 months of age, and a fourth dose between 12 and 15 months of age. All doses for each infant will be the same vaccine. The study uses a randomized design and involves two groups receiving one of the vaccines. Participants will be monitored for reactions and adverse events from the day of each vaccination through specified follow-up periods. Blood samples will be taken to measure antibody levels at multiple time points, including one month after the third and fourth doses. The total participation time is about 16 to 19 months, with some infants invited to stay longer for additional monitoring. Safety and immune response data will be collected throughout the study duration.

Researchers are evaluating normobaric hyperoxia NBO as a treatment for patients who have experienced an acute ischemic stroke and are transferred for endovascular thrombectomy EVT. The study aims to assess the effectiveness and safety of NBO in improving functional outcomes at 3 months after stroke. Stroke is a leading cause of death and disability, and although reperfusion treatments like thrombectomy improve blood flow, less than half of patients achieve favorable recovery. NBO is thought to protect the brain by rescuing hypoxic tissue and reducing damage processes, with advantages such as low cost and easy use. Participants will be randomly assigned to receive either NBO, which involves inhaling 100% oxygen alongside the best medical care, or best medical care alone. The study compares these two groups to see if NBO provides additional benefits. The treatment is given during the acute phase before or during transfer for EVT. The study includes a single-blind design and follows patients for outcomes over time. During the study, participants will have their disability level measured using the modified Rankin Scale at 90 days and one year after randomization. Other assessments include neurological function scores, imaging scans, infarct volume changes, and quality of life questionnaires at various time points. Safety and recovery progress are closely monitored throughout, with follow-up visits to track long-term effects. The total participation duration includes initial treatment and follow-up through one year.